New Treatment Options for Colorectal Cancer
Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
Frontiers | Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial -
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry | BMC Gastroenterology | Full Text
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
A) Curve for progression-free survival in patients with metastatic... | Download Scientific Diagram
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial - Annals of Oncology
Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer: an updated meta-analysis | Aging
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
A) Progression-free survival (PFS) and (B) overall survival (OS) for... | Download Scientific Diagram
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer | NEJM
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis | Scientific Reports
![PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8f71e8746365052e23ebf2293b9b25e7d432b2f6/2-Figure1-1.png "PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar")
PDF] Therapy for metastatic colorectal cancer. | Semantic Scholar
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer - ScienceDirect
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer - Medical Conferences
